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Summary The 'true' incidence of spontaneous regression of neuroblastomas is uncertain. However, the
frequency of spontaneous regression is important when the benefits of screening procedures are considered. In
the population-based Danish neuroblastoma survey 1943-80, spontaneous regression was documented in less
than 2% of cases. However, the 'true' incidence may be higher. The epidemiological findings of increased
incidence and survival rates with an unchanged mortality rate may suggest the inclusion of borderline lesions
among 'truly' malignant neuroblastomas in recent decades in Denmark. However, it is more likely to be a
result of improved diagnosis, changes in the social composition of the population and possibly unidentified
environmental agents. However, if some premalignant lesions in fact had been included, they are most likely to
be stages I-II tumours of infancy. In this study we describe cases of spontaneous regression of neuroblastoma
from the Danish population-based survey 1943-80.
Numerous anecdotal reports of cases of spontaneous remis-
sion of neuroblastomas have been published. For example, a
Danish patient diagnosed in 1941 has been the subject of
several reports (Hansen, 1953; Rosendal, 1942; Visfeldt,
1963). Neuroblastomas undergoing spontaneous regression
form 17% of the cases of spontaneous remission in man
collected from the literature by Everson and Cole (1966). In a
review of cases registered in Children's Cancer Study Group,
Evans et al. (1976) estimated the frequency to be 8% ofcases
(including stage IV-S cases). Pritchard and Kemshead (1983),
excluding stage IV-S cases, found the frequency to be only
1-2% in their experience. However, a population-based
study has not been carried out so far.
Most childhood neuroblastomas are likely to be congenital
(Birch et al., 1980; Carlsen, 1988a; Carlsen et al., 1986a;
Rubin, 1968; Sutow, 1958; Wilson & Draper, 1974), and the
prognosis is poor for most patients over the age of 2 years.
However, the benefits of a mass screening in infants (Sawada
et al., 1984a, 1987a; Scriver et al., 1987; Woods & Tuchman,
1987) has been questioned because it is argued that some
cases detected at screening might have subsequently regressed
spontaneously (Norman et al., 1987; Pastore et al., 1984).
The Danish population-based survey 1943-80 (Carlsen,
1986, 1988b; Carlsen et al., 1986a, b, 1987) offers a unique
opportunity to estimate the frequency of spontaneous regres-
sion from clinical overt disease in an unselected population
of neuroblastomas of childhood. This study reports and dis-
cusses cases of confirmed regression and also the question-
able cases. The study also considers age, stage and fate of
cases found incidentally by abdominal examination or chest
X-rays, as these cases are suggested to be equivalent to the
cases found by screening (Kosloske et al., 1987; Sawada et
al., 1988). As data from the Danish survey indicate a zero-
time shift (Bailar & Smith, 1986; Feinstein et al., 1985) in the
study period (Carlsen, 1986; Carlsen et al., 1986a, 1987), the
material was re-examined for epidemiological data suggestive
of the inclusion of premalignant lesions among the pool of
'real' neuroblastomas.
Patient population
The patient population consisted of all the 250 cases of
childhood neuroblastoma in Denmark from 1943 to 1980
(excluding five patients who were resident outside Denmark
when diagnosed) (Carlsen, 1986, 1988b; Carlsen et al., 1986a,
1987). The tumours were staged according to the system of
Evans et al. (1971) as previously reported (Carlsen et al.,
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1986b). Neuroblastoma in situ (Beckwith & Perrin, 1963;
Ikeda et al., 1981; Turkel & Itabashi, 1974), primary intra-
cerebral neuroblastomas and neuroepitheliomas of the peri-
pheral nerves were not included in the material. The hospital
records of all but two children were studied (one record lost,
one never hospitalised), and cases in which the tumour
showed possible signs of spontaneous regression were select-
ed for case reports with comments. Two of the five case
histories have previously been reported (Carlsen & Nielsen,
1980; Rechnitzer & Hansen, 1980). All the 10 stage IV-S
cases in the study period and also all 20 cases found inciden-
tally were selected for this study (Carlsen et al., 1986a, 1987),
and the secular trends offrequency of these patients and also
the trends in age and stage distribution were considered.
Case histories and discussion
Spontaneous regressionfrom clinical overt disease
Case history no. 1 An 8-month-old boy was referred to
hospital in 1958 due to paraplegia. Intravenous pyelogram
showed a mass under the left kidney. No other lesions were
detectable, and in retrospect the tumour is assigned to stage
II of Evans et al. (1971). Only biopsy was performed, which
revealed an undifferentiated tumour suggestive of a neuro-
blastoma (the histological material could not be re-examined).
No treatment was given apart from massive doses of vitamin
B12 for several years (Bodian, 1959). The tumour gradually
disappeared and the paraplegia improved over a period of 10
months. VMA excretion was normal in 1964. The patient has
been well for more than 20 years with only slight neuro-
logical sequelae.
The histological diagnosis is uncertain.
Case history no. 2 A 3-week-old boy was admitted to hospi-
tal in 1967 due to paraplegia. A mass above the right kidney
was seen on intravenous pyelogram. No other lesions were
detectable, and in retrospect the tumour is assigned to stage
II of Evans et al. (1971). VMA excretion was abnormally
high. Only biopsy was done revealing an undifferentiated
neuroblastoma. During radiotherapy consisting of 29 Gy the
tumour disappeared completely and the paraplegia improved,
but VMA excretion increased and skin metastases developed.
No further therapy was given. Multiple metastases of skin,
bone and distant lymph nodes developed within the next 2
years. They remain unchanged for 3 years, after which some
spontaneously regressed while others remained stable. Biopsy
of skin and bone metastases taken 8 and 12 years after
diagnosis showed now ganglioneuroma, and the patient,
although with neurological sequelae, has remained otherwise
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asymptomatic for more than 15 years. VMA excretion is still
abnormally high (Rechnitzer & Hansen, 1980).
Case history no. 3 A 13-month-old boy was referred to
hospital in 1961 due to a common cold. A mass was found
on abdominal examination, and an intravenous pyelogram
showed a tumour above the left kidney. No other lesions
were detectable, and the tumour is assigned to stage II of
Evans et al. (1971) in retrospect. Only biopsy was done,
which revealed an undifferentiated neuroblastoma. Radio-
therapy was given consisting of 25 Gy and the tumour dimin-
ished in size and was totally resected 1 month later by a
secondary operation. Histological examination of the tumour
revealed now only mature ganglioneuroma tissue. VMA was
normal in 1966. The patient has been well for more than 20
years (Carlsen & Nielsen, 1980).
The histological maturation following irradiation may
simply represent undifferentiated neuroblastoma-cell kill with
subsequent overgrowth of the mature ganglioneuroma ele-
ments in the tumour (Cheson et al., 1986).
Case history no. 4 A 10-month-old girl was referred to
hospital in 1968 due to paraplegia and bladder disturbances.
A lumbar myelogram showed a lumbar extradural block. An
extradural tumour with extensions in the intervertebral fora-
mina was resected by laminectomy. The histological diagno-
sis was neuroblastoma. VMA was normal after surgery. No
residual extraspinal disease could be detected by radio-
graphical examination or by abdominal exploration 2 months
later. No other lesions were detectable, and the tumour is in
retrospect assigned to stage II of Evans et al. (1971). No
further therapy was given and the patient has been well for
more than 15 years.
Beckwith and Martin (1968) have suggested that some
dumb-bell tumours might originate from dorsal root ganglia,
and neuroblastomas derived from this source might be non-
secretors of catecholamines; hence, the extraspinal compo-
nent of the tumour might have been very small.
Others have also observed that children with dumb-bell
primary neuroblastomas may be long-term survivors follow-
ing total or subtotal resection of the intraspinal, extradural
component of the mass without further treatment of the
residual extraspinal disease (Pritchard & Kemshead, 1983).
Case history no. 5 A 10-month-old girl was referred to
hospital in 1975 due to periorbital ecchymoses and
irritability. She had stage IV disease with multiple metastases
of bones, including orbital bones, distant lymph nodes and a
large abdominal mass. VMA excretion was grossly elevated.
No treatment was given initially. There was no progression
of the disease during the next 5 months. Therefore treatment
was initiated with a combination of pulsed cyclophosphamide
and vincristine at weekly intervals. The tumour responded to
treatment, and 3 months later the primary tumour was
totally resected. No irradiation was given. The bone lesions
continued to heal, and the patient achieved a complete remis-
sion after 53 weeks of treatment. The treatment was then
discontinued, and the patient has been well for more than 10
years.
The usual prolonged arrest of tumour growth may suggest
that some unknown 'regression mechanisms' probably play a
part in the complete response to treatment.
Thus, during the 38-year period covered by this study only
two cases with spontaneous regression were seen; another
three cases were observed in which some of the unusual
course of the disease could be attributed to 'spontaneous
regression mechanisms'. Together, these cases seen in 250
Danish children with neuroblastoma give an optimistic fre-
quency of 2%. The cases, distributed by decade of diagnosis,
are shown in Table I. It is seen that the frequency ranges
from 0 to 4% of cases during the four decades. It is
noticeable that all five patients were less than 14 months old
when diagnosed. Four had stage II disease, one of whom
progressed to stage IV before spontaneous regression took
place, and one had stage IV disease at diagnosis. The latter
received potentially curative treatment.
Ten stage IV-S cases were diagnosed during the study
period. One was 14 months old at diagnosis, the other nine
were less than 6 months old. Six died either as a result of the
augmented intra-abdominal pressure from the expanding
liver or from lung complications. All four survivors received
treatment (Carlsen et al., 1986a). However, as they probably
all might have recovered without treatment if the complica-
tions had been avoided or treated more appropriately (Evans
et al., 1981), all 10 patients are shown in Table I distributed
by decade of diagnosis. Patients with stage IV-S form 4% of
cases.
Incidentally discovered tumours
Tumours were found incidentally in 20 patients (Carlsen et
al., 1987) either by abdominal examination (11 patients) or
by a routine chest X-ray (nine patients) (Table I). Ten
patients had stage I disease; all have survived except one who
died from progressive disease (an infant with a sacrooccygeal
teratoma with areas of neuroblastoma among other struc-
tures (Carlsen et al., 1986a)). Eight had stage II disease; all
survived except one who died from surgical complications.
Both patients with stage III disease succumbed, one from
surgical complications, the other from progressive disease.
Only six patients were older than 3 years at diagnosis, of
whom four (all older than 5 years) had intrathoracic tumours
(Table II). Even if it is likely that only the tumours in the 14
Table I Trends in the distribution of 'probable spontaneous regressing' neuroblastomas in Denmark 1943-80
1943-49 1950-59 1960-69 1970-80 1943-80
1. Cases with unquestional spontaneous regression
2. Cases with probable spontaneous regression
3. Cases with stage IV-S disease (including 6 fatalities)
4. Cases found incidentally (including 4 fatalities)
a. Abdominal mass
b. Chest X-ray
5. Cases found incidentally less than 3 years old (including 3
fatalities)
a. Abdominal mass
b. Chest X-ray
Total number of neuroblastoma cases in each decade
Total number of long-term survivors in each decade
Survivors found incidentally (4)
Survivors from I + 2 + 3 + 5
0
or
I1(1)
I
0
1(1)
0 0
0 2(1)
0
0
27
0
0
0
o 2(1)*
0 l
48
4
I
I
Percent of long-term survivors in each decade 0% 8% 20% 33% 21%
a. Found incidentally (4) 0% 2% 3% 12% 6%
b. From 1 +2+3+5 0% 2% 10% 10% 8%
*Onepatient with aprobable spontaneous regression tumor was found incidentally. Numbers in parentheses indicate fatalities. Ten ofa total of
19 stage I patients 1943-80 were found incidentally (53%); 8 of a total of48 stage II patients were found incidentally (17%); 2 of a total of 34
stage III patients were found incidentally (6%).
2*
6(3)
2(1)*
l
0
2(1)
9(2)
6
7(2)
4
106
35
13
11
2
3*
10(6)
1 1(3)*
9(1)
9(3)*
5
250
53
16
19
69
14
2
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Table II Age, stage and survival according to clinical or incidental presentation
Age at diagnosis Stage I Stage II Stage III Stage IV Stage IV-S Unknown Total
0-5 months
clinically 1/2 6/6 1/2 0/9 3/9 0/1 11/29
incidentally 0/1 1/1 - - - - 1/2
6-11 months
clinically 2/3 6/9 0/2 2/14 - 10/28
incidentally 2/2 2/3 - - - - 4/5
12-23 months
with symptoms occurring 0/1 0/2 0/1 0/4* 1/1 - 1/9
in the first year of life
other clinically 1/1 2/5 1/9 1/20 - - 5/35
incidentally 2/2 4/4 - - - - 6/6
24-35 months
clinically - 1/2 0/5 0/25* - - 1/32
incidentally - 0/1 - - - 0/1
36-47 months
clinically 2/2 2/3 0/3 0/20 - - 4/28
incidentally 1/1 - - - - - 1/1
48-59 months
clinically - 0/2 0/2 0/9 - - 0/13
incidentally
> 60 months
clinically - 5/11 0/8 0/36* - 0/1 5/56
incidentally 4/4 - 0/1 - - - 4/5
Total
clinically 6/9 22/40 2/32 3/137 4/10 0/2 37/230
incidentally 9/10 7/8 0/2 - - - 16/20
*Six patients with stage IV disease at diagnosis had undeniable symptoms during the first year of life.
patients below 3 years of age could possibly have been found
by screening in infancy (Sawada et al., 1987a; Scriver et al.,
1987; Woods & Tuchman, 1987), all 20 patients are shown in
Table I distributed by decade of diagnosis, and the 14 cases
under 3 years of age separately. Incidental cases form only
8% of cases, but it is seen from Table I that the frequency
increased from 0 to 14% from 1943 to 1980 and, further-
more, 30% of long-term survivors 1943-80 were found
incidentally. Even if it remains a matter of speculation as to
whether some stages I-II infants diagnosed incidentally or
by screening would have regressed spontaneously (as they
almost always receive potentially curative treatment (Evans et
al., 1976)), the major criticism against mass screening is
based on this postulate (Norman et al., 1987; Pastore et al.,
1984).
If in speculating about the proportion of cases that might
have regressed spontaneously, the cases under 2 years with
stages I-II, who did not relapse and were found incidentally,
are added to the probable or confirmed spontaneous regres-
sion cases and the 10 with stage IV-S, a combined frequency
will be obtained of 26/250 = 10% of cases 'who might prob-
ably have regressed spontaneously' in Denmark 1943-80.
However, this estimate of the maximum spontaneous remis-
sion rate is highly speculative and optimistic. Long-term
survivors from this speculative group form 36% of all long-
term survivors during the study period.
The substances of Tables II and III have been published
before (Carlsen et al., 1986a, 1987), and the tables are only
added to help in understanding the issue of a possible lead-
time bias, and the speculation about the proportion of cases
that might have their prognosis influenced by a screening
programme.
Questions addressed by these data
Do epidemiological data suggest the inclusion ofpremalignant
lesions among neuroblastoma cases?
The incidence of neuroblastoma increased in Denmark dur-
ing 1943-80 to a level corresponding to that in the USA
(Young et al., 1986). The increase relates solely to children
under 5 years of age, and is most pronounced in infants
under I year. On the other hand, the mortality rate has not
changed significantly (Carlsen, 1986). During the same period
the long-term survival has gradually improved due to a
Table III Trends in the distribution of stages and ages at diagnosis in Denmark
1943-80
Survivors/total 1943-49 1950-59 1960-69 1970-80 1943-80
Below 1 year of age
Stage I 0/0 0/0 0/0 5/8 5/8
Stage II 0/1 2/2 5/8 8/8 15/19
Stage III 0/0 0/1 0/0 1/3 1/4
Stage IV 0/2 0/5 1/6 1/10 2/23
Stage IV-S 0/1 0/1 2/5 1/2 3/9
Unknown 0/0 0/1 0/0 0/0 0/1
Total below I year of age 0/4 2/10 8/19 16/31 26/64
1 year of age or older
Stage I 0/0 2/2 2/3 6/6 10/11
Stage II 0/5 0/1 3/8 11/15 14/29
Stage III 0/4 0/9 0/6 1/11 1/30
Stage IV 0/14 0/25 0/32 1/43 1/114
Stage IV-S 0/0 0/0 1/1 0/0 1/1
Unknown 0/0 0/1 0/0 0/0 0/1
Total 1 year of age or older 0/23 2/38 6/50 19/75 27/186
Per cent 1 year of age or older 85% 79% 72% 71% 74%444 N.L.T. CARLSEN
combination of a higher frequency of lower stages of the
disease (I-II), younger ages and multimodal treatment in-
cluding chemotherapy (Carlsen et al., 1986a). Thus, a striking
result from the Danish survey is the clear demonstration of a
zero-time shift (Table III). As the survivor have been fol-
lowed for at least 7 years and are considered cured, the
upward survival trend is not a simple lead-time bias, i.e.
there is earlier diagnosis but death from neuroblastoma still
occurs (Bailar & Smith, 1986; Feinstein et al., 1985). It is well
recognised that a shift in diagnostic criteria to include lesions
that have the microscopical appearance of cancer but not its
biological behaviour among truly malignant neoplasms will
result in higher incidence rates, lower stages at diagnosis and
improved survival rates, but with unchanged mortality rates
(Bailar & Smith, 1986). Thus, the data may be suggestive of
the inclusion of a proportion of 'benign' or borderline lesions
in the recent decades. The number of cases in the highly
speculative group of 'probably spontaneous regressing
tumours' cannot explain the rise in incidence on their own
(Table I), and several more plausible explanations for the rise
can be given (Carlsen, 1986, 1988b). However, the suggestion
that neuroblastomas lacking malignant behaviour are includ-
ed in the pool of 'real' neuroblastomas must be considered
seriously, as the implications are substantial. It is striking
that the prognosis was favourable for stage I disease in all
ages and stage II disease of infancy during the whole period
(Table III).
Are some stages I-lI tumours ofinfancy premalignant lesions?
There are limited data on the proportion of stage I tumours
with evidence of malignant behaviour, as they nearly always
receive potentially curative treatment (Evans et al., 1976). All
19 stage I patients in Denmark underwent complete tumour
resection with only one relapse (Carlsen et al., 1986a). In
contrast, all stage II tumours of Evans et al. (1971) have
demonstrated local invasiveness, and some the ability to
metastasise to local lymph nodes. Nineteen patients with
stage 11 disease were under one year old (Tables II and III)
and all but two received potentially curative treatment. Four
died but only two from documented progressive disease; two
others had evidence of tumour progression, one of whom
recovered spontaneously (case history 2), the other following
treatment with chemotherapy. Another infant recovered
spontaneously (case history 1). Thus, apart from local
invasiveness some stage II tumours of infancy have demon-
strated truly malignant behaviour. However, a similar pro-
portion showed spontaneous regression. Infants in stages II
and IV-S provided the majority of documented spontaneous
regression in other studies (Bodian, 1959; Evans et al., 1976;
Everson & Cole, 1966; Gross et al., 1959). It would be in
accordance with Foulds' description of the stepwise evolution
of tumours from a (benign) proliferative lesion to an increas-
ing autonomous and malignant neoplasm (Klein & Klein,
1986; Knudson & Meadows, 1980; Moolgavkar & Knudson,
1981; Nicolson, 1987) to suggest that some congenital neuro-
blastomas are dependent on external growth factors during
the first few years of life (Carlsen, 1988a), a period of pro-
liferation, differentiation and involution of the paraganglia
system (Vofite et al., 1986).
Rationalefor screening
Much evidence is compatible with the suggestion that most
neuroblastomas are congenital (Birch et al., 1980; Carlsen,
1988a; Carlsen et al., 1986a; Rubin, 1968; Sutow, 1958;
Wilson & Draper, 1974), and the age with stage distribution
strongly suggests that disseminated cases have passed
through lower undetected stages at younger ages before they
are diagnosised (Carlsen, 1988a). The disease is notorious for
its vagueness of symptoms (Carlsen et al., 1987; Wilson &
Draper, 1974) and, as age under one year and stages I-II
disease have a crucial effect on prognosis, paediatric
oncologists emphasise the importance of a good abdominal
examination whenever a child is seen by a physician, and
mass screening programmes in infants have been proposed
(Sawada et al., 1984a, 1987a; Scriver et al., 1987; Woods &
Tuchman, 1987). Table II shows the number of neuroblas-
toma patients in Denmark found at each age, either clinically
or incidentally. One can speculate as to whether the prog-
nosis of all patients with stages III-IV disease diagnosed
between age 6 and 47 months (104/250 = 42%) could be
influenced by screening at age 6 months, provided that 65%
of all childhood neuroblastomas could be detected clinically
or by screening before or at 6 months, as suggested from
Japan (Sawada et al., 1987b) (the cumulative percentage of
cases reaches 65% between age 3 and 4 years in Denmark).
The lead-time in this estimate is, however, considerably
longer than suggested by Pastore et al. (1984). In this context
it is noticeable that of 11 patients with undeniable signs of
the disease in the first year of life (Carlsen, 1986), nine were
diagnosed between age 12 and 23 months, one at 25 months
and one at 94 months (Table II).
What can we learnfrom the preliminary results ofscreening in
Japan?
In the recent birth cohorts in Denmark (Carlsen, 1986) and
in the USA (Young et al., 1986) 1 in 7,000 live births will
develop neuroblastoma before 15 years of age. If 65% of all
childhood neuroblastomas could be detected before or at the
age of 6 months, as suggested in Japan (Sawada et al.,
1987b), then the expected prevalence by screening at age 6
months would be approximately 1 in 11,000 live births (65/
100 x 1/7,000). However, the proof that screening can only
detect cases that would have progressed to clinical disease
depends on an appropriate fall in the incidence in older
children and a decline in mortality rate (Carlsen, 1988a;
Draper, 1988; Mauer, 1988). It is therefore of some concern
that the incidence appears to increase with screening in Japan
(Nishi et al., 1987; Sawada, 1986; Sawada et al., 1984a, b, c)
so that now 1 in 5,000 is detected at 6 months of age (Nishi
et al., 1987; Sawada et al., 1987a, b). This prevalence appears
to be substantially higher than the cumulative birth cohort
incidence rate under the age of 15 years in Denmark and the
USA. The fact that screen-detected early stage tumours
(Hayashi et al., 1988; Kaneko et al., 1987, 1988) are not
believed to evolve into advanced stage tumours from a
cytogenetic viewpoint, is of equal concern. Both studies of
screen-detected tumours were missing the early stage tumours
with near-diploidy or hypo-tetraploidy with structural abnor-
malities associated with older children and poor prognosis
(Hayashi et al., 1988; Kaneko et al., 1987).
What are we dealing with? Is a substantial proportion of
the screen-detected cases in Japan spontaneous regressing
tumours, or not malignancies at all? Neuroblastoma in situ
(Beckwith & Perrin, 1963, Ikeda et al., 1981; Turkel &
Itabashi, 1974), which most likely is a normal variation in the
morphogenesis of the adrenal gland, has been found by
random autopsy studies in infants under 3 months old in
incidences of 1 in 179 to 1 in 259 (Beckwith & Perrin, 1963).
Could some screen-detected cases virtually be neuroblastoma
in situ cases?
Tentative conclusions
The prognosis remains poor for most patients with neuro-
blastoma who are diagnosed at unfavourable ages and stages
due to the vagueness of symptoms. Therefore, screening for
the disease is desirable.
Most data concerning the natural history of this tumour
are compatible with the suggestion that they are often con-
genital. Therefore, screening should be done as soon after
birth as possible. However, the proof of the hypothesis
depends on the finding that a higher frequency of cases
found in infancy by screening will eventually be followed by
an appropriate fall in the number of cases diagnosed at older
ages and a decline in mortality rate.
The occasional observation of spontaneous regression ofSPONTANEOUS REMISSION OF NEUROBLASTOMAS 445
tumours in infants and the rare observation of the same
phenomenon in older children is compatible with the concept
that tumours develop by a series of changes from a depen-
dent to an increasingly autonomous and malignant neoplasm.
Insufficient data exist concerning the frequency of stages
I-II tumours of infancy that are dependent tumours, which
might regress spontaneously. Therefore, stages I-II cases of
infancy should be treated cautiously with the possibility of
regression in mind.
Screening studies should not be undertaken unless there
exists a reliable incidence and mortality rate for the popula-
tion to allow close observation of the epidemiological rates.
Furthermore, cases found by screening should be intensively
studied for karyotypic pattern, oncogene expression and cell-
ular DNA content, among others.
I am indepted to Drs P.V. Bro, G. Erichsen, B. Hamborg-Pedersen,
U. Hesselbjerg and H. Schroeder for the collection of this patient
population.
References
BAILAR, J.C. III & SMITH, E.M. (1986). Progress against cancer? N.
Engi. J. Med., 314, 126.
BECKWITH, J.B. & MARTIN, R.F. (1968). Observations of the his-
topathology of neuroblastoma. J. Pediatr. Surg., 3, 106.
BECKWITH, J.B. & PERRIN, E.V. (1963). In situ neuroblastoma: a
contribution to the natural history of neural crest tumors. Am. J.
Pathol., 43, 1089.
BIRCH, J.M., MARSDEN, H.B. & SWINDELL, R. (1980). Incidence of
malignant disease in childhood: a 24-year review of the Man-
chester Children's Tumour Registry data. Br. J. Cancer, 42, 215.
BODIAN, M. (1959). Neuroblastoma. Pediatr. Clin. North Am., 6,
449.
CARLSEN, N.L.T. (1986). Epidemiological investigations on neuro-
blastomas in Denmark 1943-1980. Br. J. Cancer, 54, 977.
CARLSEN, N.L.T. (1988a). Annotation. Why age has independent
prognostic significance in neuroblastomas. Evidence for intra-
uterine development, and implications for the treatment of the
disease. Anticancer Res., 8, 255.
CARLSEN, N.L.T. (1988b). Regional differences in incidence of
neuroblastoma in Denmark in 1943-1980. Ugeskr. Lager., 150,
2511.
CARLSEN, N.L.T., CHRISTENSEN, I.J., SCHROEDER, H. & 5 others
(1986a). Prognostic factors in neuroblastomas treated in Den-
mark from 1943 to 1980. A statistical estimate of prognosis based
on 253 cases. Cancer, 58, 2726.
CARLSEN, N.L.T., CHRISTENSEN, I.J., SCHROEDER, H. & 4 others
(1986b). Prognostic value of different staging systems in neuro-
blastomas and completeness of tumour excision. Arch. Dis.
Child., 61, 832.
CARLSEN, N.L.T. & NIELSEN, O.H. (1980). Abdominal neuroblas-
tomas. An analysis of 48 cases. Ugeskr. Lager., 142, 2972.
CARLSEN, N.L.T., SCHROEDER, H., CHRISTENSEN, I.J. & 4 others
(1987). Signs, symptoms, metastatic spread and metabolic
behaviour of neuroblastomas treated in Denmark during the
period 1943-1980. Anticancer Res., 7, 465.
CHESON, B.D., JASPERSE, D.M., CHUN, H.G. & FRIEDMAN, M.A.
(1986). Differentiating agents in the treatment of human malig-
nancies. Cancer Treat. Rev., 13, 129.
DRAPER, G.J. (1988). Screening for neuroblastoma. Br. Med. J., 297,
152.
EVANS, A.E., BAUM, E. & CHARD, R. (1981). Do infants with stage
IV-S neuroblastoma need treatment? Arch. Dis. Child., 56, 271.
EVANS, A.E., D'ANGIO, G.J. & RANDOLPH, J. (1971). A proposed
staging for children with neuroblastoma. Cancer, 27, 374.
EVANS, A.E., GERSON, J. & SCHNAUFER, L. (1976). Spontaneous
regression of neuroblastoma. Natl Cancer Inst. Monogr., 44, 49.
EVERSON, T.C. & COLE, W.H. (1966). Spontaneous Regressing of
Cancer. W.B. Saunders: Philadelphia.
FEINSTEIN, A.R., SOSIN, D.M. & WELLS, C.K. (1985). The Will
Rogers phenomenon. Stage migration and new diagnostic techni-
ques as a source of misleading statistics for survival in cancer. N.
Engi. J. Med., 312, 1604.
GROSS, R.E., FARBER, S. & MARTIN, L.W. (1959). Neuroblastoma
sympatheticum. A study and report of 217 cases. Pediatrics, 23,
1179.
HANSEN, P.B. (1953). Sympathicoblastoma of the adrenal medulla
with osseous metastases. Acta Radiol., 40, 500.
HAYASHI, Y., INABA, T., HANADA, R. & YAMAMOTO, K. (1988).
Chromosome findings and prognosis in 15 patients with neuro-
blastoma found by VMA mass screening. J. Pediatr., 112, 567.
IKEDA, Y., LISTER, J., BOUTON, J.M. & BUYUKPAMUKCU, M.
(1981). Congenital neuroblastoma, neuroblastoma in situ, and the
normal fetal development of the adrenal. J. Pediatr. Surg., 16,
636.
KANEKO, Y., KANDA, N., MASEKI, N. & 5 others (1987). Different
karyotypic patterns in early and advanced stage neuroblastomas.
Cancer Res., 47, 311.
KANEKO, Y., MASEKI, N., SAKURAI, M. & 4 others (1988).
Chromosomes and screening for neuroblastoma. Lancet, i, 174.
KLEIN, G. & KLEIN, E. (1986). Conditioned tumorigenicity of
activated oncogenes. Cancer Res., 46, 3211.
KNUDSON, A.G. & MEADOWS, A.T. (1980). Regression of neuroblas-
toma IV-S: a genetic hypothesis. N. Engi. J. Med., 302, 1254.
KOSLOSKE, A.M., BHATTACHARYYA, N. & DUNCAN, M.H. (1987).
'Incidental' neuroblastoma. Lancet, ii, 565.
MAUER, A.M. (1988). Screening for neuroblastoma. J. Pediatr., 112,
576.
MOOLGAVKAR, S.H. & KNUDSON, A.G. (1981). Mutation and
cancer: a model for human carcinogenesis. J. Natl Cancer Inst.,
66, 1037.
NICOLSON, G.L. (1987). Tumor cell instability, diversification and
progression to the metastatic phenotype: From oncogene to
oncofetal expression. Cancer Res., 47, 1473.
NISHI, M., MIYAKE, H., TAKEDA, T. & 4 others (1987). Effects of the
mass screening of neuroblastoma in Sapporo City. Cancer, 60,
433.
NORMAN, M.G., DIMMICK, J.E. & TEASDALE, M. (1987). Screening
for neuroblastoma. Lancet, ii, 565.
PASTORE, G., MERLETTI, F. & MAGNANI, C. (1984). Screening for
neuroblastoma. Lancet, ii, 752.
PRITCHARD, J. & KEMSHEAD, J. (1983). Neuroblastoma: recent
developments in assessment and mangement. In Paediatric
Oncology, Duncan, E.W. (ed.) p. 69. Springer-Verlag: Heidelberg.
RECHNITZER, C. & HANSEN, S.W. (1980). Maturation of neuroblas-
toma. Long-term survival with disseminated osseous metastases.
Ugeskr. Lager., 142, 2976.
ROSENDAL, T. (1942). Two cases of sympathicoblastoma of the
suprarenal gland with metastases to the cranium and the tubular
bones. Acta Radiol., 23, 462.
RUBIN, P.R. (1968). Comment. Cure and the growth rate of child-
hood tumors. JAMA, 205, 113.
SAWADA, T. (1986). Outcome of 25 neuroblastomas revealed by
mass screening in Japan. Lancet, i, 377.
SAWADA, T., HIRAYAMA, M., NAKATA, T. & 10 others (1984a).
Mass screening for neuroblastoma in infants in Japan. Lancet, ii,
271.
SAWADA, T., KAWAKATU, H., HORII, Y. & SUGIMOTO, T. (1988).
Incidental neuroblastoma. Lancet, i, 364.
SAWADA, T., KAWAKATU, H. & SUGIMOTO, T. (1987a). Screening
for neuroblastoma. Lancet, ii, 1204.
SAWADA, T., KIDOWAKI, T., SAKAMOTO, 1. & 4 others (1984b).
Neuroblastoma. Mass screening for early detection and its prog-
nosis. Cancer, 53, 2731.
SAWADA, T., KIDOWAKI, T., SUGIMOTO, T. & KUSUNOKI, T.
(1984c). Incidence of neuroblastoma in infancy in Japan. Med.
Pediatr. Oncol., 12, 101.
SAWADA, T., SUGIMOTO, T., TANAKA, T. & 4 others (1987b).
Number and cure rate of neuroblastoma cases detected by the
mass screening program in Japan: future aspects. Med. Pediatr.
Oncol., 15, 14.
SCRIVER, C.R., GREGORY, D., BERNSTEIN, M. & 7 others (1987).
Feasibility of chemical screening of urine for neuroblastoma case
finding in infancy in Quebec. Can. Med. Assoc. J., 136, 952.
SUTOW, W.W. (1958). Prognosis in neuroblastoma of childhood. Am.
J. Dis. Child., 96, 299.
TURKEL, S.B. & ITABASHI, H.H. (1974). The natural history of
neuroblastic cells in the fetal adrenal gland. Am. J. Pathol., 76,
225.
VISFELDT, J. (1963). Transformation of sympathicoblastoma into
ganglioneuroblastoma. Acta Pathol. Microbiol. Scand., 58, 414.446 N.L.T. CARLSEN
VOUJTE, P.A., DE KRAKER, J. & BURGERS, J.M.V. (1986). Tumours of
the sympathetic nervous system. In Cancer in Children, 2nd edn,
Vouite, P.A., Barrett, A., Bloom, H.J.G., Lemerle, J. & Neid-
hardt, M.K. (eds) p. 238. Springer-Verlag: Berlin, Heidelberg,
New York, Tokyo.
WILSON, L.M.K. & DRAPER, G.J. (1974). Neuroblastoma, its natural
history and prognosis: a study of 487 cases. Br. Med. J., 3, 301.
WOODS, W.G. & TUCHMAN, M. (1987). Neuroblastoma: the case for
screening infants in North America. Pediatrics, 79, 869.
YOUNG, J.L., RIES, L.G., SILVERBERG, E., HORM, J.W. & MILLER,
R.W. (1986). Cancer incidence, survival, and mortality for child-
ren younger than age 15 years. Cancer, 58, 598.